Fresenius SE KGaA Valuation
Is 1FRE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 1FRE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1FRE (€32.75) is trading below our estimate of fair value (€83.16)
Significantly Below Fair Value: 1FRE is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1FRE?
Key metric: As 1FRE is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 1FRE's PS Ratio? | |
|---|---|
| PS Ratio | 0.8x |
| Sales | €22.81b |
| Market Cap | €18.49b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.4x |
| Enterprise Value/EBITDA | 14.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 1FRE's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.2x | ||
AMP Amplifon | 2.3x | 7.5% | €5.3b |
DIA DiaSorin | 4.7x | 7.7% | €5.6b |
SRI Servizi Italia | 0.2x | 2.6% | €69.0m |
LH Labcorp Holdings | 1.6x | 4.7% | US$19.7b |
1FRE Fresenius SE KGaA | 0.8x | 3.6% | €18.5b |
Price-To-Sales vs Peers: 1FRE is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (2.2x).
Price to Sales Ratio vs Industry
How does 1FRE's PS Ratio compare vs other companies in the European Healthcare Industry?
| 7 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 7 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 1FRE is expensive based on its Price-To-Sales Ratio (0.8x) compared to the European Healthcare industry average (0.6x).
Price to Sales Ratio vs Fair Ratio
What is 1FRE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.8x |
| Fair PS Ratio | 1.4x |
Price-To-Sales vs Fair Ratio: 1FRE is good value based on its Price-To-Sales Ratio (0.8x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €32.75 | €40.06 +22.3% | 12.5% | €53.00 | €30.00 | n/a | 15 |
| Nov ’25 | €33.92 | €39.67 +17.0% | 11.3% | €50.00 | €30.00 | n/a | 15 |
| Oct ’25 | €34.15 | €39.41 +15.4% | 11.1% | €50.00 | €30.00 | n/a | 15 |
| Sep ’25 | €33.43 | €38.64 +15.6% | 12.9% | €50.00 | €30.00 | n/a | 15 |
| Aug ’25 | €31.82 | €38.64 +21.4% | 12.9% | €50.00 | €30.00 | n/a | 15 |
| Jul ’25 | €28.37 | €37.26 +31.3% | 14.1% | €50.00 | €28.00 | n/a | 16 |
| Jun ’25 | €29.26 | €36.73 +25.5% | 14.8% | €50.00 | €28.00 | n/a | 16 |
| May ’25 | €27.91 | €36.22 +29.8% | 15.0% | €50.00 | €28.00 | n/a | 16 |
| Apr ’25 | €24.95 | €36.22 +45.2% | 15.0% | €50.00 | €28.00 | n/a | 16 |
| Mar ’25 | €25.86 | €38.21 +47.7% | 25.0% | €70.00 | €28.00 | n/a | 17 |
| Feb ’25 | €25.98 | €38.59 +48.5% | 24.1% | €70.00 | €30.00 | n/a | 17 |
| Jan ’25 | €33.68 | €38.66 +14.8% | 24.6% | €70.00 | €30.00 | n/a | 16 |
| Dec ’24 | €29.10 | €38.48 +32.2% | 25.1% | €70.00 | €29.60 | n/a | 16 |
| Nov ’24 | €24.25 | €38.51 +58.8% | 23.7% | €68.00 | €29.60 | €33.92 | 16 |
| Oct ’24 | €29.51 | €38.63 +30.9% | 24.1% | €68.00 | €29.60 | €34.15 | 16 |
| Sep ’24 | €29.40 | €38.01 +29.3% | 24.6% | €68.00 | €28.00 | €33.43 | 17 |
| Aug ’24 | €28.71 | €36.59 +27.5% | 27.5% | €69.00 | €27.00 | €31.82 | 17 |
| Jul ’24 | €24.76 | €36.41 +47.1% | 28.6% | €69.00 | €26.00 | €28.37 | 16 |
| Jun ’24 | €25.66 | €38.17 +48.8% | 41.2% | €92.00 | €26.00 | €29.26 | 15 |
| May ’24 | €26.12 | €37.11 +42.1% | 43.8% | €92.00 | €22.00 | €27.91 | 15 |
| Apr ’24 | €24.74 | €35.83 +44.8% | 46.1% | €92.00 | €16.60 | €24.95 | 16 |
| Mar ’24 | €25.16 | €35.23 +40.0% | 47.6% | €92.00 | €16.60 | €25.86 | 16 |
| Feb ’24 | €26.50 | €35.53 +34.1% | 47.0% | €92.00 | €16.60 | €25.98 | 16 |
| Jan ’24 | €26.39 | €35.06 +32.9% | 48.1% | €92.00 | €16.60 | €33.68 | 16 |
| Dec ’23 | €26.15 | €35.83 +37.0% | 48.0% | €92.00 | €16.60 | €29.10 | 15 |
| Nov ’23 | €23.21 | €35.63 +53.5% | 47.0% | €92.00 | €16.60 | €24.25 | 16 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Fresenius Medical Care
€12.2b
Provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally.
1FME
€41.73
7D
4.5%
1Y
19.5%
Amplifon
€5.3b
Engages in the distribution of hearing solutions and the fitting of customized products that help people rediscover various emotions of sound in Europe, the Middle East, Africa, the Americas, and the Asia Pacific.
AMP
€23.68
7D
-6.1%
1Y
-15.9%
Garofalo Health Care
€511.9m
Operates healthcare clinics in Italy.
GHC
€5.78
7D
5.9%
1Y
23.8%